Summit Therapeutics Inc. (SMMT)
Health Care ยท Pharmaceutical Preparations
Summit Therapeutics Inc. (SMMT) is listed on Nasdaq, where its shares have traded since March 5, 2015. SentiSense covers Summit Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Robert Duggan and Maky Zanganeh is its chief executive officer. The company reports 265 employees, and its corporate website is www.smmttx.com.
About Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Latest reported results
Summit Therapeutics Inc. reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended September 30, 2026, 209 institutions reported holding SMMT, with 65.5 million shares worth $1.1 billion in aggregate. The largest reported holders were Vanguard, BlackRock and FMR. Of the 5 largest reported holders, 2 added shares and 3 reduced their positions during the quarter.
More on SMMT
- SMMT sentiment: whether news and social coverage of Summit Therapeutics Inc. leans bullish or bearish, and the stories driving it.
- SMMT ownership: all 209 reporting institutions, plus insider and congressional trades.
- SMMT financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Summit Therapeutics Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Summit Therapeutics Inc. do?
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.
What sector is SMMT in?
SentiSense classifies Summit Therapeutics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does SMMT stock trade?
Summit Therapeutics Inc. (SMMT) is listed on Nasdaq, where its shares have traded since March 5, 2015.
Who is the CEO of Summit Therapeutics Inc.?
Robert Duggan and Maky Zanganeh is the chief executive officer of Summit Therapeutics Inc..